Shilpa Medicare
Shilpa Medicare Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
What the Q1 FY27 call signalled
2 of 5 strong
The short version
Oncology API growth depends on molecule success and market commoditization; strong end-customer interest exists before investment. The company expects steady and robust growth across key verticals with improved operating leverage leading to higher margins and ROCE in coming years.
From Shilpa Medicare's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Oncology API growth depends on molecule success and market commoditization; strong end-customer interest exists before investment.
- Formulations have over 50% captive production, supporting stable growth.
- Biologics segment shows robust potential, growing at 42% YoY, expected to have significantly higher growth due to a smaller base and industry shift towards biologics.
- Biologics strategy is mixed: short-to-mid term focus on biosimilars and CDMO; long-term on strategic partnerships with high potential products.
- CDMO business is a key growth driver, with over 25 NCE programs in development and the potential for multiple commercial launches next year.
- API growth driven by specialty CDMO and capacity expansion, with selective investments ongoing.
2 more points from Shilpa Medicare's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Shilpa Medicare said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No significant new capital expenditure (capex) expected in Biologics or Albumin divisions as existing investments and capacities are underutilized and sufficient for growth in coming years.
- Additional capex continues in the API division and some new Formulation molecules where higher capacity utilization requires more investment.
- Capacity utilization in Bangalore, Jadcherla, and Dharwad plants is monitored; segmental utilization details available on request.
- Overall approach prioritizes sweating existing assets while selectively investing in areas with growth potential.
Fundraising & Capital Structure
See what Shilpa Medicare said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Shilpa Medicare currently has more than 25 NCE (New Chemical Entity) programs in various development stages across the group.
- They have 3 late-stage NCE programs expected to enter the commercial phase next year (FY27).
- On the CDMO side, the company has over 20 customers actively engaged.
- For oncology APIs, investments are made only when there is an end-customer already interested, providing good visibility on orders.
2 more points from Shilpa Medicare's call on order book
Create a free account to keep reading this call
Shilpa Medicare — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹437 Cr, net profit ₹108 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Shilpa Medicare Ltd's management said in earlier quarters
- Q3 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Shilpa Medicare and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Shilpa Medicare Q1 FY27 results?
Oncology API growth depends on molecule success and market commoditization; strong end-customer interest exists before investment. The company expects steady and robust growth across key verticals with improved operating leverage leading to higher margins and ROCE in coming years.
What is Shilpa Medicare share price analysis?
Shilpa Medicare currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 64.5 with a market cap of ₹18,338 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shilpa Medicare planning capital expenditure?
No significant new capital expenditure (capex) expected in Biologics or Albumin divisions as existing investments and capacities are underutilized and sufficient for growth in coming years.
Keep Shilpa Medicare on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.